Menu

Artificial Tissues Implanted Without Regulatory Approval, Investigation Reports

Tissue recipients were treated as “guinea pigs,” says investigation leader.

Oct 3, 2017
Ashley P. Taylor

PIXABAY, DEBORABALVESSynthetic tissues from University College London that had not yet been approved for human use were sent abroad and implanted into humans, an investigation into the university’s regenerative medicine program has found.

The patients who received the transplants were used as “guinea pigs,” University of Edinburgh’s Stephen Wigmore, who led the investigation, tells The Guardian.

A 26-year-old patient in Tehran, Iran, received a synthetic graft to bypass the femoral artery, according to the report. A patient in Mumbai, India, was implanted with plastic discs beneath the skin to test their biocompatibility. These tissues were all most likely manufactured in the lab of Alexander Seifalian, The Guardian reports. Seifalian was fired from UCL in 2016 for reasons unrelated to his research.

According to New Scientist, the investigation initiated by UCL follows up on the institution’s relationship with Paolo Macchiarini, who was fired from the Karolinska Institute in 2016 after six of eight patients in whom he had implanted synthetic windpipes died. The first windpipe Macchiarini implanted, into a 36-year-old Eritrean man who was among the patients who died, came from Seifalian’s lab. Macchiarini also held an honorary professorship at UCL.

UCL professor of vascular surgery George Hamilton told the investigators that the femoral artery graft was likely to become infected and result in amputation or even death.

Hamilton and Seifalian shared supervision of the PhD student who made an artificial tear duct, which was implanted into a patient in Zurich, Switzerland, The Guardian reports. The two professors tell The Guardian that they only learned of the tear-duct implantation after the fact. And Hamilton adds that he does not feel responsible for devices from his lab being used against regulations.

“The implantation was the job of the surgeon, who requires getting ethical approval and [regulatory] approval. This was not my job,” Seifalian tells New Scientist.

“We deeply regret that materials . . . that had not undergone rigorous pre-clinical assessment and which were not made to GMP [good manufacturing practice] standards, were manufactured and supplied by Professor Alexander Seifalian's research laboratory for direct clinical use. Our governance systems should have prevented that. We also regret the wider, negative impact that this work had on the field of regenerative medicine research,” a UCL release states.

 

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing